Geron (GERN) said Wednesday it appointed Harout Semerjian as president and chief executive officer, starting Thursday.
Semerjian succeeds Dawn Carter Bir, who has been serving as interim president and CEO since March. Bir will continue her role on the company's board, the biopharmaceutical company said.
Semerjian was most recently the CEO of GlycoMimetics, Geron said.
Shares of Geron were up more than 9% in recent trading.
Price: 1.31, Change: +0.11, Percent Change: +9.17
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.